Company intelligence / Profile preview
SparX Biopharmaceutical
Mount Prospect, Illinois, United Statessparxbio.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
First patient dosed with SPX-303 (anti-LILRB2/PD-L1 bispecific antibody) in April 2024. FDA approved IND application for SPX-303 in October 2023.
- Therapeutic areas
- Oncology
- Modalities
- AntibodiesBispecific antibodiesAntibody-drug conjugates (ADCs)Multi-specific antibodies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Arovella Therapeutics (for CLDN18.2-CAR-iNK development)
Beyond the preview
Go deeper on SparX Biopharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SparX Biopharmaceutical.